RadNet, has received FDA clearance for the third-generation release of its Quantib Prostate 3.0 MRI artificial intelligence (AI) software, enhancing the offering with updated tools. 

Quantib Prostate software for MRI reading support was first introduced in the US, followed by a class IIb CE marking in Europe in 2021.

Quantib Prostate 3.0 is an AI-based software solution that advances the MRI prostate reporting workflow and its output for radiologists and urologists. It provides a suite of tools to improve reporting quality and speed, including AI-based segmentations and volumetry, PSA density calculation, precise registration and movement correction, one-click segmentation of lesion candidates, PI-RADS scoring support, and standardised reporting to facilitate easy and comprehensive communication of results.

The FDA 510(k) special clearance introduces an upgrade to the latest Quantib Prostate 2.1 release. The upcoming release of the product will include an improved prostate and sub-region segmentation algorithm, automated drawing of the lesions on the PI-RADS sector map, and other functionalities that will enhance the user experience.

Arthur Post Uiterweer, CEO of Quantib, said: “We are excited to present this update of Quantib Prostate, which enables us to continue to support our customers with the newest developments and improved AI algorithm performance. We strive to regularly and continuously improve our software in order to support radiologists and urologists in the best possible way.”

Gregory Sorensen, M.D., president of RadNet’s AI Division, added: “The approval of Quantib Prostate 3.0 represents another step forward in advancing prostate cancer care by bringing the latest in AI technology to MRI interpretation. With the increasing recognition of the important role MRI plays in prostate cancer diagnosis, physicians value the power that this software puts in their hands even more.”